Search results
Bristol Myers Squibb Cancer-Treatment Trial Misses Endpoint
The Wall Street Journal· 1 hour agoHEALTH NEWS Bristol Myers Squibb said on Friday that its trial evaluating a combination of cancer...
Bristol Myers' Opdivo-Yervoy combo meets main goal in liver cancer trial
Reuters via Yahoo News· 2 months agoThe treatment, tested in patients with advanced hepatocellular carcinoma (HCC), met the main goal of...
Bristol Myers' Opdivo+Yervoy Fails To Meet Survival Endpoint In Untreated Urothelial Cancer
Benzinga via Yahoo Finance· 2 years agoBristol Myers Squibb & Co's (NYSE: BMY) Phase 3 CheckMate -901 trial of Opdivo (nivolumab) plus...
Advanced Lung Cancer and Immunotherapy
Verywell Health via Yahoo News· 8 months agoImmunotherapy is a newer class of treatment for lung and other cancers. It primes the body’s natural immune system to fight back against cancer....
Bristol Myers' (BMY) Opdivo Label Expansion Filings Get Accepted
Zacks via Yahoo Finance· 3 months agoBristol Myers (BMY) announces the acceptance of its regulatory filings for the perioperative Opdivo...
Bristol Myers (BMY) Announces Upbeat Data From NSCLC Study
Zacks via Yahoo Finance· 11 months agoBristol Myers (BMY) reports encouraging four-year clinical efficacy results from its lung cancer...
Bristol Myers' (BMY) Opdivo Meets Main Goal in Melanoma Study
Zacks via Yahoo Finance· 2 years agoBristol Myers' (BMY) immuno-oncology drug Opdivo demonstrates a statistically significant and...
Bristol Myers' (BMY) Opdivo Combos Get FDA Nod for ESCC
Zacks via Yahoo Finance· 2 years agoBristol Myers (BMY) secures an FDA approval for two Opdivo-based regimens as the first-line...
Mesothelioma
Health· 1 week agoThana Prasongsin / Getty Images Medically reviewed by Brian Bezack, DO Mesothelioma is an aggressive cancer of the tissues that line the mesothelium, the...
Bristol-Myers (BMY) Q3 Earnings Beat, Sales Decline Y/Y
Zacks via Yahoo Finance· 2 years agoBristol-Myers Squibb Company BMY reported decent results for the third quarter of 2022. The company...
